General
Preferred name
DALFAMPRIDINE
Synonyms
fampridine ()
4-Aminopyridine methiodide ()
4-Aminopyridine ()
4-AP ()
4-Pyridinamine ()
Ampyra ()
4-aminopyridine, Neurorecovery ()
Fampyra ()
NSC-15041 ()
Fampridine ()
Fampridine (4-aminopyridine) ()
Fampridina ()
Fampridine accord ()
EL-970 ()
Ampyra Extended Release ()
P&D ID
PD001882
CAS
504-24-5
Tags
available
drug
Approved by
FDA
First approval
2010
Drug indication
Obstructive sleep apnea
Multiple sclerosis
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Fampridine is the INN for this compound, whereas its USAN is dalfampridine. (GtoPdb)
ABSORPTION Orally-administered dalfampridine is rapidly and completely absorbed from the gastrointestinal tract. ; Tmax, immediate release form = 1 hour;; Tmax, extended release form = 3.5 hours;; Cmax, 10 mg extended release = 17.3 - 21.6 ng/mL; ; Relative bioavailability of 10 mg extended-release tablets compared to aqueous oral solution = 96%
MOA In MS, axons are progressively demyelinated which exposes potassium channels. As a result, there is a leak of potassium ions which results in the repolarization of cells and a decrease in neuronal excitability. The overall impact is the impairment of neuromuscular transmission as it is harder to trigger an action potential. ; Dalfampridine inhibits voltage-gated potassium channels in the CNS to maintain the transmembrane potential and prolong action potential. In other words, dalfampridine works to make sure that the current available is high enough to stimulate conduction in demyelinated axons that are exposed in MS patients. Furthermore, it facilitates neuromuscular and synaptic transmission by relieving conduction blocks in demyelinated axons.
ROE Almost all of the dose and its metabolites are completely eliminated by the kidneys after 24 hours. ; Urine (96%; 90% of total dose as unchanged drug);; Feces (0.5%)
TOXICITY LD50, oral, mouse = 19 mg/kg; LD50, oral, rat = 21 mg/kg
HALF-LIFE Immediate release form = 3.5 hours;; Extended release form = 5.47 hours;
PRICE 29
DESCRIPTION Dalfampridine is a potassium channel blocker. It is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis. (Enamine Bioactive Compounds)
DESCRIPTION Induces depolarization of GABA neurons; weak non-selective ;K+-channel blocker; anticonvulsant (LOPAC library)
DESCRIPTION Non-selective KV channel blocker (Tocriscreen Total)
DESCRIPTION NMDA antagonist; less active enantiomer of (+)-MK 801 (Tocris Bioactive Compound Library)
DESCRIPTION 4-Aminopyridine (Dalfampridine) is a nonselective potassium (K+) channel blocker that binds to the cytoplasmic side of the cell membrane. (TargetMol Bioactive Compound Library)
Compound Sets
30
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
JUMP-Target 1 Compound Set
LOPAC library
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Total
External IDs
117
Properties
(calculated by RDKit )
Molecular Weight
94.05
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
1
Aromatic Ring Count
1
cLogP
0.66
TPSA
38.91
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.51
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Custom attributes
(extracted from source data)
Selectivity
A-type
Target
Potassium Channel
KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2
KCNH7
Primary Target
Voltage-gated Potassium (KV) Channels
MOA
Blocker
potassium channel blocker
Indication
multiple sclerosis
Pathway
Membrane Transporter/Ion Channel
Source data